Connexios: Harnessing the Indian cost advantage in network biology
This article was originally published in Scrip
Executive Summary
Imagine if a start-up company could afford to hire enough high-calibre scientists to spend years creating a detailed map of a broad and complex pathology like metabolic disease, incorporating large amounts of cellular and molecular biological data, into which it could plug further swathes of clinical information. Imagine if it was then able to evaluate existing drug R&D against this map, and identify promising areas for potential future drug discovery and development, which it would then proceed to carry out itself. All with the financial backing of an enthusiastic private investor. It seems unlikely, but this is precisely what Connexios Life Sciences has done. Scrip's companies editor Eleanor Malone met CEO Dr Suri Venkatachalam to find out more.